|Dr. Francois R. Martelet M.D.||Chief Exec. Officer||5.27M||N/A||1960|
|Mr. Fredrik Jarrsten||Chief Financial Officer||N/A||N/A||1967|
|Mr. Kai Wilkinson||Chief Technical Officer||N/A||N/A||1981|
|Dr. Reinhard Koenig||Chief Scientific Officer||N/A||N/A||1960|
|Mr. Urban Ekelund||IR Mang.||N/A||N/A||N/A|
|Ms. Och Annette Ljungmark||Head of Accounting and HR||N/A||N/A||1950|
|Mr. John T. Cosby||Head of Regulatory Affairs||N/A||N/A||1962|
|Mr. Dzianis Babrou||Head of Product Devel.||N/A||N/A||N/A|
|Mr. Henrik Rönnberg||Chief Medical Officer of Animal Health||N/A||N/A||N/A|
|Maria Nilsson Hagberg||Head of Regulatory Affairs||N/A||N/A||N/A|
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Vivesto AB’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 10; Board: 1; Shareholder rights: 1; Compensation: 9.